Bausch Health Companies Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $1.7B normalized FCF base (vs. TTM FCF of $1.43B, adjusted modestly upward to reflect stabilized cash generation across its Salix, Bausch+Lomb-adjacent, and international pharma segments); 3% annual FCF growth for years 1-5; 2% for years 6-10; 12% discount rate; 2.5% terminal growth; $18.95B net debt; 373.99M shares outstanding.

Reasoning: Bausch Health carries a very large legacy debt load and ongoing litigation overhang from its Valeant-era history, so a high 12% discount rate and low growth are used; even with a modestly optimistic normalized FCF assumption, its enormous net debt leaves only a small residual equity value, consistent with the stock's low, volatile trading price.